Diferencia entre revisiones de «Amoxicillin»

(Restore original dosing content alongside dynamic SMW tables)
(Remove disease-specific dosing covered by dynamic SMW tables)
Línea 9: Línea 9:
===General===
===General===
*500-875mg PO q12
*500-875mg PO q12
===[[Strep Pharyngitis]]===
*1000mg PO q24h x 10 days<ref>CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html</ref>


===[[Otitis Media]]===
===[[Otitis Media]]===
Línea 66: Línea 63:
**First Dose: 12.5-22.5mg/kg PO x 1
**First Dose: 12.5-22.5mg/kg PO x 1
**Max: 875mg/dose
**Max: 875mg/dose
===[[Otitis Media]]===
{{OM amox peds treatment}}
===Community Acquired [[Pneumonia]]===
*90mg/kg/day PO divided q12h x 5-10 days
*First Dose: 45mg/kg PO x 1
**Max
***3 months - 4 years: 500mg/dose
***>5 years: 4000mg/day


===[[Strep Pharyngitis]]===
===[[Strep Pharyngitis]]===

Revisión del 02:57 20 mar 2026

General

  • Type: Amino-Penicillin
  • Dosage Forms: oral solution, capsule, tablet, chewable tablet, extended release tablet
  • Dosage Strengths: oral solution: 125, 200, 250, 400mg/5 mL; capsule: 250, 500mg; tablet: 500, 875mg; chewable tablet: 125, 250mg; extended release tablet: 775mg
  • Routes of Administration: PO
  • Common Trade Names: Amoxil; Moxatag, Trimox

Adult Dosing

General

  • 500-875mg PO q12

Otitis Media

  • 1000mg PO q8h x 10 days

Sinusitis

  • 1000mg PO q8h x 10 days

Dental Abscess

  • 1000mg PO x 1, then 500mg PO q8h x 3 days
  • If I&D

Chlamydial Cervicitis/Urethritis

  • 500mg PO q8h x 7 days
  • For pregnant patients

Lyme Disease

  • 500mg PO q8h x 14-21 days

Salmonella

Not 1st line treatment

  • Acute
    • Immunocompetent
      • 500mg PO q8h x 3-7 days
    • Immunocompromised
      • 1000mg PO q8h x 3-14 days
  • Chronic carrier
    • 1000mg PO q8h x 3 months

Typhoid Fever

Not 1st line treatment

  • 50-100mg/kg/day PO divided q6-8h x 14 days
  • First Dose: 12.5mg-33.3mg/kg PO x 1


Indications by Disease

DiseaseDoseContext
Chlamydia trachomatis500mg PO q8h x 7 days; For pregnant patientsChlamydial Cervicitis/Urethritis
Dental abscess1000mg PO x 1, then 500mg PO q8h x 3 days; If I&DDental Abscess
Endocarditis2g or 50mg/kgDental Procedure Prophylaxis
Lyme disease500mg PO q8h x 14-21 daysLyme Disease
Periorbital cellulitis875 mg BIDOutpatient
Pneumonia (main)1 g three times dailyOutpatient, Healthy
SalmonellaNot 1st line treatment; Acute; Immunocompetent; 500mg PO q8h x 3-7 days; Immunocompromised; 1000mg PO q8h x 3-14 days; Chronic carrier; 1000mg PO q8h x 3 monthsSalmonella
Sinusitis1000mg PO q8h x 10 daysSinusitis
Streptococcal pharyngitis50 mg/kg once daily (maximum = 1000 mg) for 10 daysPenicillin Options
Typhoid feverNot 1st line treatment; 50-100mg/kg/day PO divided q6-8h x 14 days; First Dose: 12.5mg-33.3mg/kg PO x 1Typhoid Fever

Pediatric Dosing

General

  • <3mo: 20-30mg/kg/day PO divided q12h
    • First Dose: 10-15mg/kg PO x 1
    • Max: 30mg/kg/day
  • >3mo: 25-45mg/kg/day PO divided q12h
    • First Dose: 12.5-22.5mg/kg PO x 1
    • Max: 875mg/dose

Strep Pharyngitis

  • 50mg/kg PO q24h x 10 days[1]
  • Max: 1000mg/day

Sinusitis

  • 90mg/kg/day PO divided q8-12h x 10 days
  • Max: 1000mg/dose

H. pylori

  • 50mg/kg/day PO divided BID x 7-14 days
  • Max: 2000mg/day

Early Lyme Disease

  • 50mg/kg/day PO divided q8h x 14-21 days
  • First Dose: 16.6mg/kg PO x1
  • Max: 500mg/dose

Salmonella (>3mo)

  • 50-100mg/kg/day PO divided q8-12h
    • Acute: x 3-7 days
    • Acute Immunocompromised: 10-14 days
    • Chronic: 3 months

Typhoid Fever (>3mo)

Not 1st line treatment

  • 50-100mg/kg/day PO divided q6-8h x 14 days


Indications by Disease

DiseaseDoseContext
Acute otitis media30mg/kg/day PO divided q12h x 10 daysInitial, <2 months
Acute otitis media80-90mg/kg/day PO divided q12h x 10 daysInitial, 2mo-5yr
Acute otitis media80-90mg/kg/day PO divided q12h x 5-10 daysInitial, 6-12yr
Dental abscess50mg/kg/day PO divided TID x 7-10 days (max 1.5g/day)Pediatric Outpatient
Endocarditis50mg/kg PO (max 2g) 1hr before procedurePediatric Dental Prophylaxis
Helicobacter pylori50mg/kg/day PO divided BID x 7-14 days; Max: 2000mg/dayH. pylori
Lyme disease50mg/kg/day PO divided q8h x 14-21 days; First Dose: 16.6mg/kg PO x1; Max: 500mg/doseEarly Lyme Disease
Periorbital cellulitis45-90 mg/kg per day divided every 12 hoursOutpatient
Pharyngitis50mg/kg PO q24h x 10 days'"`UNIQ--ref-0000003F-QINU`"'; Max: 1000mg/dayStrep Pharyngitis
Pneumonia (peds)45mg/kg/dose BID x 5-7 days POOutpatient
Salmonella50-100mg/kg/day PO divided q8-12h; Acute: x 3-7 days; Acute Immunocompromised: 10-14 days; Chronic: 3 monthsSalmonella (>3mo)
Sinusitis90mg/kg/day PO divided q8-12h x 10 days; Max: 1000mg/doseSinusitis
Streptococcal pharyngitis50mg/kg PO once daily x 10 days (max 1000mg)Pediatric First Line
Typhoid feverNot 1st line treatment; 50-100mg/kg/day PO divided q6-8h x 14 daysTyphoid Fever (>3mo)

Special Populations

  • Pregnancy Rating: B
  • Lactation: Use caution
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Anaphylaxis
  • Hypersensitivity vasculitis
  • SJS/TEN
  • Pseudomembranous colitis

Common

  • Diarrhea, nausea/vomiting
  • Rash
  • Headache
  • AST/ALT elevation
  • Mucocutaneous candidiasis
  • Serum sickness-like reactions
  • Anemia, leukopenia, thrombocytopenia, eosinophilia
  • Hyperactivity, anxiety, insomnia, confusion behavioral changes
  • Tooth discoloration

Pharmacology

  • Half-life: 3.7 hr (neonates), 1-2 hr (infants and children), 0.7 - 1.4 hr (adults)
  • Metabolism: Hepatic
  • Excretion: Urine
  • Mechanism of Action: Inhibits bacterial cell wall synthesis

Antibiotic Sensitivities[2]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep I
Strep. anginosus gp S
Enterococcus faecalis S
Enterococcus faecium I
MSSA R
MRSA R
CA-MRSA R
Staph. Epidermidis R
C. jeikeium R
L. monocytogenes S
Gram Negatives N. gonorrhoeae R
N. meningitidis S
Moraxella catarrhalis R
H. influenzae I
E. coli I
Klebsiella sp R
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg R
Enterobacter sp, AmpC pos R
Serratia sp R
Serratia marcescens X1
Salmonella sp I
Shigella sp I
Proteus mirabilis S
Proteus vulgaris R
Providencia sp. R
Morganella sp. R
Citrobacter freundii R
Citrobacter diversus R
Citrobacter sp. R
Aeromonas sp R
Acinetobacter sp. R
Pseudomonas aeruginosa R
Burkholderia cepacia R
Stenotrophomonas maltophilia R
Yersinia enterocolitica R
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida S
Haemophilus ducreyi R
Vibrio vulnificus X1
Misc Chlamydophila sp R
Mycoplasm pneumoniae R
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces S
Bacteroides fragilis R
Prevotella melaninogenica S
Clostridium difficile X1
Clostridium (not difficile) S
Fusobacterium necrophorum S
Peptostreptococcus sp. S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. ↑ CDC Website, accessed 2026-28-01. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html
  2. ↑ Sanford Guide to Antimicrobial Therapy 2014


Obtenido de «https://www.wikem.org/w/index.php?title=Amoxicillin&oldid=386633»